Why is Now the TiME to Start Testing for Lymphedema? A Critical Look at the Evidence, Workflow, and Reimbursement
Dr. Peter Beitsch, Surgical Oncologist, Director Dallas Breast Cancer & North Texas Melanoma Center
Dr. Walt Taylor, Breast & Melanoma Surgeon, Texas Health Physician’s Group
Dr. Pat Whitworth, Breast Surgical Oncologist & Director, Nashville Breast Center
Why is now the TiME to start testing for lymphedema?
Join Targeted Medical Education (TME) and special guests as they explore the evidence: bioimpedance spectroscopy (BIS) represents best practice for prospective surveillance to reduce the impact of lymphedema. Join this LIVE event and learn from experts how to overcome the challenges of implementation into practice including evidence, workflows, and reimbursement. It’s TiME to ask the question, how do I provide this care for my patients?
- Does the evidence support routine screening for lymphedema among breast cancer patients
- How SOZO fits into existing workflows to test patients with minimal staff burden
- What is the latest reimbursement landscape for testing lymphedema patients using SOZO
Peter Beitsch, MD, Surgical Oncologist, Director Dallas Breast Center & North Texas Melanoma Center
Walt Taylor, MD, FACS, Breast & Melanoma Surgeon, Texas Health Physician’s Group
Pat Whitworth, MD, FACS, Breast Surgical Oncologist & Director, Nashville Breast Center
Learn More About SOZO®
SOZO uses ImpediMed’s BIS technology to measure and track critical information about the human body to aid clinicians in managing chronic disease and maximizing patient health. SOZO is non-invasive, fast, and easy to use. Results from the 30-second test* are available immediately providing proactive patient care including early detection of disease progression, treatment monitoring, and patient education.
*As tested on AndroidContact Us